Osteoprotegerin as a marker of cardiovascular risk in children and adolescents with type 1 diabetes.
Elevated osteoprotegerin (OPG) levels have been reported in patients with diabetes complications. We investigated whether plasma OPG levels can be used as a marker of cardiovascular risk in children and adolescents with type 1 diabetes (T1D).



Plasma blood samples were obtained from 243 subjects (143 children and adolescents with T1D and 100 healthy controls). OPG concentrations were measured by enzyme-linked immunosorbent assay (ELISA) method. All data were analyzed by using PASW statistics 18.



A significant higher plasma OPG level was found in children with T1D compared to controls (p < 0.001). A significant increase of OPG levels has been related to the glucose level ≥ 7 mmol/L (2.44 [0.01-6.22] vs. 2.16 [0.13-6.22] pmol/L, p = 0.019), microalbuminuria ≥ 30 mg/24 h (3.71 [0.160-6.03] vs. 2.26 [0.01-6.22] pmol/L, p < 0.001), and cystatin-C ≥ 0.789 mg/L (2.64 [0.37-6.22] vs. 2.11 [0.01-5.82] pmol/L, p < 0.001). We noted a significant higher frequency of children with increased cystatin-C levels in the group with elevated plasma level of OPG compared with those with normal levels (49 vs. 18%, respectively) with an odds ratio (OR) = 4.42 [1.41-13.84] (p = 0.006). We showed a significant increase of OPG levels when the number of cardiovascular risk factors exceeds 3 (p = 0.001).



OPG may be a potential biomarker of cardiovascular risk in T1D. Implementation of OPG determination in the clinical laboratory setting would be useful in order to better stratify patients and to assess the most adequate treatment.
Laboratory of Biochemistry and Toxicology, Monastir's University Hospital, Monastir, Tunisia.|Biochemistry Department, Sahloul's University Hospital, Sousse, Tunisia.
Ons
O
Fekih
Laboratory of Biochemistry and Toxicology, Monastir's University Hospital, Monastir, Tunisia.
Hamdi
H
Triki
Laboratory of Biochemistry and Toxicology, Monastir's University Hospital, Monastir, Tunisia.|Biochemistry Department, Sahloul's University Hospital, Sousse, Tunisia.
Sonia
S
Triki
Laboratory of Biochemistry and Toxicology, Monastir's University Hospital, Monastir, Tunisia.|Biochemistry Department, Sahloul's University Hospital, Sousse, Tunisia.
Fadoua
F
Neffati
Pediatric Department, Monastir's University Hospital, Monastir, Tunisia.
Slaheddine
S
Chouchane
Pediatric Department, Monastir's University Hospital, Monastir, Tunisia.
Mohamed Neji
MN
Guediche
Laboratory of Biochemistry and Toxicology, Monastir's University Hospital, Monastir, Tunisia.
Mohamed Fadhel
MF
Najjar
D000293:Adolescent; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D015897:Comorbidity; D055316:Cystatin C / Q000097:blood; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000453:epidemiology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D008297:Male; D053244:Osteoprotegerin / Q000097:blood*; D015203:Reproducibility of Results; D012307:Risk Factors; D014416:Tunisia / Q000453:epidemiology; D015854:Up-Regulation
D015415:Biomarkers; D001786:Blood Glucose; D055316:Cystatin C; D006442:Glycated Hemoglobin; D053244:Osteoprotegerin; C525030:CST3 protein, human; C506030:TNFRSF11B protein, human; C517652:hemoglobin A1c protein, human
cardiovascular risk; diabetes complications; osteoprotegerin; type 1 diabetes